LAEKNA-B (02105) signs a clinical cooperation agreement with Lilly.

LAEKNA-B (02105) announced that the group has signed a clinical cooperation agreement with Eli Lilly and Company (Lilly) (NYSE: LLY) to support and accelerate the global clinical development of LAE102 for the treatment of obesity. Lilly will be responsible for conducting a Phase I study in the United States and will bear the related expenses. The group retains the global rights to LAE102. The group is committed to bringing this precision treatment to overweight and obese patients who require new treatment options to achieve high-quality weight control. LAE102 is a monoclonal antibody developed targeting Act RIIA, a receptor that plays a significant role in muscle regeneration and fat metabolism. In preclinical models, LAE102 has shown the effect of increasing muscle and reducing fat. When used in combination with GLP-1 receptor agonists, LAE102 can further reduce fat and significantly decrease the muscle loss caused by GLP-1 receptor agonists, making LAE102 a candidate drug for high-quality weight control.